NTLA

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Intellia Therapeutics Inc

NASDAQ | NTLA

25.89

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 23, 2025)

$2.78B

Market Cap

-

P/E Ratio

-4.69

EPS

$28.25

52 Week High

$5.90

52 Week Low

HEALTHCARE

Sector

NTLA Chart

Recent Chart
Price Action

NTLA Technicals

Tags:

NTLA Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $48M
Total Revenue $58M
Cost Of Revenue $10M
Costof Goods And Services Sold $10M
Operating Income -$534M
Selling General And Administrative $126M
Research And Development $466M
Operating Expenses $582M
Investment Income Net -
Net Interest Income $48M
Interest Income $48M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $10M
Income Before Tax -$519M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$519M
Comprehensive Income Net Of Tax -
Ebit -$534M
Ebitda -$524M
Net Income -$519M

Revenue & Profitability

Earnings Performance

NTLA Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $1.2B
Total Current Assets $640M
Cash And Cash Equivalents At Carrying Value $189M
Cash And Short Term Investments $189M
Inventory -
Current Net Receivables $8.5M
Total Non Current Assets $551M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $304M
Short Term Investments $412M
Other Current Assets $30M
Other Non Current Assets -
Total Liabilities $319M
Total Current Liabilities $111M
Current Accounts Payable $15M
Deferred Revenue -
Current Debt -
Short Term Debt $20M
Total Non Current Liabilities $208M
Capital Lease Obligations $210M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $210M
Other Current Liabilities $55M
Other Non Current Liabilities -
Total Shareholder Equity $872M
Treasury Stock -
Retained Earnings -$2.2B
Common Stock $10K
Common Stock Shares Outstanding $99M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$349M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $10M
Capital Expenditures $5.8M
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $126M
Cashflow From Financing $186M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$519M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $48M
Total Revenue $58M
Cost Of Revenue $10M
Costof Goods And Services Sold $10M
Operating Income -$534M
Selling General And Administrative $126M
Research And Development $466M
Operating Expenses $582M
Investment Income Net -
Net Interest Income $48M
Interest Income $48M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $10M
Income Before Tax -$519M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$519M
Comprehensive Income Net Of Tax -
Ebit -$534M
Ebitda -$524M
Net Income -$519M

NTLA News

NTLA Profile

Intellia Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Intellia Therapeutics, Inc. (NTLA) is a pioneering gene editing company based in Cambridge, Massachusetts, specializing in the development of transformative therapies for genetic disorders using its proprietary CRISPR/Cas9 technology. The company is advancing a diverse pipeline of innovative treatment candidates currently in clinical trials, underscoring its commitment to precision medicine. As a frontrunner in the gene editing landscape, Intellia benefits from a strong intellectual property foundation and strategic collaborations that enhance its growth potential and influence within the biotechnology sector.

YYAI
-50.60%
$0.09
BYND
-20.67%
$2.84
SCNX
+354.94%
$2.60
YDKG
+5.58%
$0.07
F
-0.72%
$12.34
CGBS
-39.47%
$0.03
VHAI
0.00%
$0.00
RGTI
+9.80%
$39.59
AIRE
+38.18%
$0.98
RIG
+13.74%
$3.89
TSLA
+2.28%
$448.98
INTC
+3.35%
$38.15
BURU
-5.27%
$0.34
VTYX
+70.98%
$6.60
NOK
+11.17%
$6.17
QBTS
+13.81%
$31.06
NVDA
+1.04%
$182.16
T
-3.63%
$24.62
ADAP
-3.44%
$0.07
MSAI
+101.73%
$1.35
AAL
+5.62%
$12.77
BITF
+5.71%
$4.16
VIVK
+5.68%
$0.26
WTO
-7.04%
$0.06
IONZ
-14.59%
$3.98
AREB
+75.34%
$3.77
AXDX
-61.36%
$0.03
DNN
+0.36%
$2.73
IONQ
+7.06%
$59.37
PLUG
-1.36%
$2.88
ABEV
+0.45%
$2.21
SMCI
-8.72%
$47.92
QUBT
+7.19%
$15.94
TLRY
+2.06%
$1.48
VZ
-3.51%
$38.40
RGTZ
-20.27%
$14.90
GRAB
+1.77%
$5.72
SOFI
+3.27%
$28.08
RBNE
+7.87%
$1.37
BBD
+1.51%
$3.35
JOBY
+1.29%
$15.67
RF
-0.04%
$24.10
WGRX
+9.03%
$0.40
CAN
+3.22%
$1.76
ETHD
-3.17%
$3.97
ACHR
+0.46%
$10.91
QS
+7.95%
$14.66
SGBX
+29.82%
$2.96
RMBL
+60.50%
$3.21
AMD
+2.06%
$234.99
BTG
+0.38%
$5.23
ADD
-25.47%
$0.05
VLY
+4.24%
$10.56
ONDS
+4.74%
$7.06
GPUS
-0.28%
$0.38
PLTR
+2.84%
$180.48
LAES
+5.92%
$5.72
RXRX
-0.34%
$5.73
SRM
+53.27%
$10.30
CIFR
+7.10%
$17.25
PFE
-0.20%
$24.67
TNGX
-13.04%
$7.53
UUUU
-6.50%
$21.26
BTBT
+3.62%
$3.72
AAPL
+0.43%
$259.58
MARA
+0.36%
$19.22
AMC
-0.72%
$2.73
DVLT
+5.14%
$2.25
WBD
+3.50%
$21.25
AMZN
+1.44%
$221.09
IREN
+7.77%
$55.86
HPE
+0.43%
$23.19
PBR
+0.93%
$11.84
NIO
+0.73%
$6.89
IBIO
-8.63%
$1.27
CUTR
-10.19%
$0.09
KMI
-4.75%
$26.25
NVTS
+0.03%
$13.61
WLGS
-5.57%
$0.04
SOUN
+2.70%
$18.23
SCWO
+32.07%
$0.48
LUV
-6.25%
$31.65
RR
+7.11%
$5.42
TE
-9.73%
$3.71
ETWO
0.00%
$3.30
SNAP
+1.28%
$7.87
BAC
+1.29%
$51.76
RIVN
+1.31%
$13.09
BTE
+5.72%
$2.40
APLD
+9.01%
$33.38
VALE
-0.52%
$11.46
HOOD
+5.58%
$134.33
DNUT
+1.98%
$4.11
LUMN
+10.65%
$7.79
AFMD
-34.94%
$0.18
NCLH
-0.63%
$23.48
ERIC
-0.31%
$9.48
CLSK
+4.80%
$17.67
NAKA
+10.41%
$0.79
KDLY
+10.41%
$0.79
YYAI
-50.60%
$0.09
BYND
-20.67%
$2.84
SCNX
+354.94%
$2.60
YDKG
+5.58%
$0.07
F
-0.72%
$12.34
CGBS
-39.47%
$0.03
VHAI
0.00%
$0.00
RGTI
+9.80%
$39.59
AIRE
+38.18%
$0.98
RIG
+13.74%
$3.89
TSLA
+2.28%
$448.98
INTC
+3.35%
$38.15
BURU
-5.27%
$0.34
VTYX
+70.98%
$6.60
NOK
+11.17%
$6.17
QBTS
+13.81%
$31.06
NVDA
+1.04%
$182.16
T
-3.63%
$24.62
ADAP
-3.44%
$0.07
MSAI
+101.73%
$1.35
AAL
+5.62%
$12.77
BITF
+5.71%
$4.16
VIVK
+5.68%
$0.26
WTO
-7.04%
$0.06
IONZ
-14.59%
$3.98
AREB
+75.34%
$3.77
AXDX
-61.36%
$0.03
DNN
+0.36%
$2.73
IONQ
+7.06%
$59.37
PLUG
-1.36%
$2.88
ABEV
+0.45%
$2.21
SMCI
-8.72%
$47.92
QUBT
+7.19%
$15.94
TLRY
+2.06%
$1.48
VZ
-3.51%
$38.40
RGTZ
-20.27%
$14.90
GRAB
+1.77%
$5.72
SOFI
+3.27%
$28.08
RBNE
+7.87%
$1.37
BBD
+1.51%
$3.35
JOBY
+1.29%
$15.67
RF
-0.04%
$24.10
WGRX
+9.03%
$0.40
CAN
+3.22%
$1.76
ETHD
-3.17%
$3.97
ACHR
+0.46%
$10.91
QS
+7.95%
$14.66
SGBX
+29.82%
$2.96
RMBL
+60.50%
$3.21
AMD
+2.06%
$234.99
BTG
+0.38%
$5.23
ADD
-25.47%
$0.05
VLY
+4.24%
$10.56
ONDS
+4.74%
$7.06
GPUS
-0.28%
$0.38
PLTR
+2.84%
$180.48
LAES
+5.92%
$5.72
RXRX
-0.34%
$5.73
SRM
+53.27%
$10.30
CIFR
+7.10%
$17.25
PFE
-0.20%
$24.67
TNGX
-13.04%
$7.53
UUUU
-6.50%
$21.26
BTBT
+3.62%
$3.72
AAPL
+0.43%
$259.58
MARA
+0.36%
$19.22
AMC
-0.72%
$2.73
DVLT
+5.14%
$2.25
WBD
+3.50%
$21.25
AMZN
+1.44%
$221.09
IREN
+7.77%
$55.86
HPE
+0.43%
$23.19
PBR
+0.93%
$11.84
NIO
+0.73%
$6.89
IBIO
-8.63%
$1.27
CUTR
-10.19%
$0.09
KMI
-4.75%
$26.25
NVTS
+0.03%
$13.61
WLGS
-5.57%
$0.04
SOUN
+2.70%
$18.23
SCWO
+32.07%
$0.48
LUV
-6.25%
$31.65
RR
+7.11%
$5.42
TE
-9.73%
$3.71
ETWO
0.00%
$3.30
SNAP
+1.28%
$7.87
BAC
+1.29%
$51.76
RIVN
+1.31%
$13.09
BTE
+5.72%
$2.40
APLD
+9.01%
$33.38
VALE
-0.52%
$11.46
HOOD
+5.58%
$134.33
DNUT
+1.98%
$4.11
LUMN
+10.65%
$7.79
AFMD
-34.94%
$0.18
NCLH
-0.63%
$23.48
ERIC
-0.31%
$9.48
CLSK
+4.80%
$17.67
NAKA
+10.41%
$0.79
KDLY
+10.41%
$0.79
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.